Update on the Management of Diabetic Neuropathy
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
IN BRIEF Distal symmetric polyneuropathy (DSPN) and diabetic autonomic neuropathies, particularly cardiovascular autonomic neuropathy (CAN), are prevalent diabetes complications with high morbidity, mortality, and amputation risks. The diagnosis of DSPN is principally a clinical one based on the presence of typical symptoms combined with symmetrical, distal-to-proximal stocking-glove sensory loss. CAN is an independent risk factor for cardiovascular mortality, arrhythmia, silent ischemia, major cardiovascular events, and myocardial dysfunction. Screening for CAN in high-risk patients is recommended. Symptoms of gastroparesis are nonspecific and do not correspond with its severity. Diagnosis of gastroparesis should exclude other factors well documented to affect gastric emptying such as hyperglycemia, hypoglycemia, and certain medications. There is a lack of treatment options targeting the neuropathic disease state. Managing neuropathic pain also remains a challenge. Given the high risk of addiction, abuse, psychosocial issues, and mortality, opioids are not recommended as first-, second-, or third-line agents for treating painful DSPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Persons with prediabetes and/or obesity may also develop DPN.547,548,553”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [553]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“However, a multifactorial intervention that included a lifestyle component and targeted glucose and cardiovascular disease risk factors reduced the risk of CAN by 60% in people with type 2 diabetes (1,45).”
BackgroundGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 8×
“Tramadol and other opioids have also shown some efficacy on DSPN pain in large multicenter trials (1,49,58).”
BackgroundResultInfluentialDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 15×
“DSPN affects primarily the sensory nerves, and the symptoms and signs vary according to the type of sensory fibers involved (1,5).”
BackgroundSelf-citationYoung, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“Contemporary prevalence rates for DSPN remain high, occurring in at least 20% of people with type 1 diabetes of >20 years’ duration (1,6,7), 10–15% of people with newly diagnosed type 2 diabetes (1,8,9), and 10–30% of subjects with impaired glucose tolerance (IGT) or metabolic syndrome (1,3,4).”
BackgroundIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“In contrast, enhanced glucose control in people with type 2 diabetes reduces the risk of developing DSPN modestly (5–9% relative risk reduction) (41,42) and selectively (10,43).”
BackgroundSelf-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211 · cited 2×
“This discrepancy highlights the difference between type 1 and type 2 diabetes and emphasizes the point that many people with type 2 diabetes develop DSPN despite adequate glucose control (10,41), likely because of asymptomatic hyperglycemia for many years before the diagnosis of type 2 diabetes, the presence of multip…”
Background
Research works printed but not linked: 1
- Jaiswal M, Divers J, Isom S, Prevalence and correlates of cardiovascular autonomic neuropathy in youth with type 1 diabetes: SEARCH for Diabetes in Youth Study [Abstract]. Diabetes 2014; 63: A145
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationLu, Y., Xing, P., Cai, X., Luo, D., Li, R., Lloyd, C. E., Sartorius, N., & Li, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.534372 · Cited by 148
“As a major contributor to peripheral nerve injury (4), DPN impairs quality of life and potentiates risks of disability in diabetic subjects (5).”
BackgroundLin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Self-citationSpectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 105
Self-citationİzgü, N., Metin, Z. G., Karadaş, C., Özdemir, L., Metinarikan, N., & Çorapçıoğlu, D. (2020) · Journal of Nursing Scholarship · doi:10.1111/jnu.12580 · Cited by 78
Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M. (2020) · Diabetes Care · doi:10.2337/dc19-1582 · Cited by 59
“The tests only detect neuropathy at an advanced stage (8,9).”
BackgroundPathophysiology and management of diabetic gastroenteropathy
Meldgaard, T., Keller, J., Olesen, A. E., Olesen, S. S., Krogh, K., Borre, M., Farmer, A., Brock, B., Brock, C., & Drewes, A. M. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819852047 · Cited by 56
Effect of Acupuncture on Diabetic Neuropathy: A Narrative Review
Cho, E., & Kim, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168575 · Cited by 65
“Current approaches to the management of diabetic neuropathy focus on glycemic control, lifestyle modifications (such as diet and exercise), and drug-based pain management [13].”
BackgroundCardiovascular autonomic neuropathy: A silent killer with long reach
Ang, L., Dillon, B., Mizokami-Stout, K., & Pop-Busui, R. (2020) · Autonomic Neuroscience · doi:10.1016/j.autneu.2020.102646 · Cited by 53
Self-citationThe conundrum of diabetic neuropathies—Past, present, and future
Ang, L. P., Mizokami‐Stout, K., Eid, S., Elafros, M. A., Callaghan, B. C., Feldman, E. L., & Pop‐Busui, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108334 · Cited by 66
Self-citationDiabetic neuropathy: Pathogenesis and evolving principles of management
Zaino, B., Goel, R., Devaragudi, S., Prakash, A., Vaghamashi, Y., Sethi, Y., Patel, N., & Kaka, N. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101582 · Cited by 63
Diabetes: how to manage diabetic peripheral neuropathy
Gandhi, M., Fargo, E. L., Prasad‐Reddy, L., Mahoney, K. M., & Isaacs, D. M. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-2 · Cited by 38
Screening for diabetic peripheral neuropathy in resource-limited settings
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01032-x · Cited by 45
Sun, Q., Zhang, B., Zhang, P., Hu, J., Zhang, H., & Xu, G. (2019) · Molecular Pain · doi:10.1177/1744806919838659 · Cited by 31
“However, painkillers, the main treatment, referring to other neuropathic pain, are ineffective and insufficient to many diabetic pain patients.(4) Therefore, it is believed that diabetic neuropathic pain has its own special pathogenesis.”
BackgroundHeart Rate Variability and Pregnancy Complications: Systematic Review
Sharifi-Heris, Z., Rahmani, A. M., Axelin, A., Rasouli, M., & Bender, M. (2023) · Interactive Journal of Medical Research · doi:10.2196/44430 · Cited by 35
Acupuncture for painful diabetic peripheral neuropathy: a systematic review and meta-analysis
Zhou, L., Wu, T., Zhong, Z., Yi, L., & Li, Y. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1281485 · Cited by 23
“The current management approaches for diabetic neuropathy concentrate on controlling glycemia, implementing lifestyle changes such as diet and physical activity, and utilizing medication-based pain relief (9).”
BackgroundLi, Z., Lei, X., Xu, B., Wang, S., Gao, T., & Lv, H. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9257 · Cited by 30
Corneal nerve fiber loss in diabetes with chronic kidney disease
Tummanapalli, S. S., Issar, T., Yan, A., Kwai, N. C. G., Poynten, A. M., Krishnan, A. V., Willcox, M. D. P., & Markoulli, M. P. (2019) · The Ocular Surface · doi:10.1016/j.jtos.2019.11.010 · Cited by 22
Inflammatory Markers and Measures of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes
Ang, L. P., GUNARATNAM, S. V. G., Huang, Y., Dillon, B. R., Martin, C. L., Burant, A., Reiss, J., Blakely, P. K., Vasbinder, A. L., Zhao, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036787 · Cited by 18
Self-citationSathienluckana, T., Palapinyo, S., Yotsombut, K., Wanothayaroj, E., Sithinamsuwan, P., & Suksomboon, N. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2306866 · Cited by 18
“Additionally, the combination treatment is also taken to treat overtly negative symptoms (Ang et al., 2018).”
BackgroundAlizadeh, S. D., Jahani, S., Rukerd, M. R. Z., Tabrizi, R., Masoumi, R., Banihashemian, S. Z., Tabatabaei, M. S. H. Z., Ghodsi, Z., Pour‐Rashidi, A., Harrop, J. S., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04033-3 · Cited by 14
Zhao, W., Lu, J., Zhang, L., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002140 · Cited by 11
“Correspondence to: Jian Zhou, Department of Endocrinology and Metabolism, Diabetic sensorimotorpolyneuropathy (DSPN) isoneof the most common complications of diabetes affecting up to 50% of all patients and is associated with high morbidity andahighriskof lower limbamputation.([1]) Importantly,up to50%ofDSPNmaybeasymp…”
BackgroundEffects of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline on a diabetic neuropathic pain model
Tokhi, A., Ahmed, Z. S., Arif, M., Rehman, N. U., Sheibani, V., Sewell, R. D. E., & Rauf, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1128496 · Cited by 11
“Despite the prevalence of DPN, currently available centrally acting drug treatments such as antidepressants, anticonvulsants and opioids pose serious challenges by virtue of their frequency of adverse effects, modest efficacy and dependence proclivity (Ang et al., 2018; Fisher et al., 2021).”
BackgroundVekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10
“Until recently, therapeutic options to modify the course of DPN beyond symptom management were limited [17, 18].”
Factors Associated With Mild Cognitive Impairment in Patients With Type 2 Diabetes: A Cohort Study
Tlemçani, F. Z. R., Elamari, S., Motaib, I., Laidi, S., Idrissi, N. A., Ahid, S., & Chadli, A. (2022) · Cureus · doi:10.7759/cureus.28305 · Cited by 12
“Peripheral sensory neuropathy was detected by testing pain evoked by light touch according to Michigan Neuropathy Screening Instrument scores [10].”
MethodEndocrine, nutritional, and metabolic diseases
Nesterova, A. P., Климов, Е. А., Жаркова, М. С., Sozin, S., Соболев, В. В., Ivanikova, N. V., Shkrob, M., & Yuryev, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817086-1.00004-x · Cited by 9
Hassan, H., Ganguli, S., Rashed, H. M., Johnson, W. D., Bhandari, B., & Abell, T. L. (2021) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-020-02300-y · Cited by 8
Kostopoulos, D., Rizopoulos, K., McGilvrey, J., Hauskey, J., Courcier, J., Connor-Israel, K., Koster, H., & von Leden, R. E. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/9970124 · Cited by 10
“Traditionally, treatment for DPN has focused mainly on drug therapies, which are associated with multiple side e ff ects, including lethargy, somnolence, and increased risk of falls [12 – 17].”
The prevalence of diabetic peripheral neuropathy in youth with diabetes mellitus
Sophausvaporn, P., Boonhong, J., & Sahakitrungruang, T. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2244092.046 · Cited by 10
Bolster, M., Dietzel, J., Habermann, I. V., Hörder, S., Brinkhaus, B., & Stöckigt, B. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05064-w · Cited by 4
“When asked about the effect of DPN symptoms on their everyday lives, half of the participants reported not feeling restricted in everyday life or only considered the polyneuropathy a minor nuisance: “None [restriction] actually, only slightly annoying, but otherwise not at all” [4].”
InfluentialAnandan, C., Horak, H. A., Patel, K., & AANEM (2025) · Muscle & Nerve · doi:10.1002/mus.70015 · Cited by 5
Sohrabi, K., Ahmadi, H., Amini, A., Ahrabi, B., Mostafavinia, A., Omidi, H., Mirzaei, M., Fathabady, F. F., Fridoni, M., Rahmannia, M., et al. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00178-z · Cited by 4
“Despite these excessive financial costs, roughly 20 percentage of D.M. individuals have remained untreated DFUs during the first year of disease [8].”
BackgroundDiabetic peripheral neuropathy: Person-centered care
Anastasi, J. K., & Klug, C. (2021) · Nursing · doi:10.1097/01.nurse.0000736904.62783.68 · Cited by 6
Tannus, L. R. M., Pedrosa, H. C., Aguiar, C. H., Drummond, K. R. G., Pinheiro, A., Leal, F. S. L., Negrato, C. A., & Gomes, M. B. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.08.001 · Cited by 4
Luo, N., Zeng, Y.-C., Fu, B.-T., Low, J. W., & Fang, J. (2024) · Journal of Pain Research · doi:10.2147/jpr.s472648 · Cited by 3
“6 Nonetheless, the exact relationship between high blood sugar levels and the onset, advancement, and intensity of neuropathy is not fully understood.”
Exploring the efficacy of plant-based nutraceuticals in managing diabetic neuropathy
Khan, S., Markoulli, M. P., Tsoi, A. T., & Willcox, M. D. P. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01793-z · Cited by 2
“Currently, approaches for managing diabetic neuropathy rely on glycemic control, modifications in lifestyle such as dietary interventions and exercise, and drug-based pain relief (Ang et al. 2018).”
Arya, D. K., Pèrié, L., Mohanta, G. C., Mishra, R., Kumar, Y., Picot, C. R., & Verma, N. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119218 · Cited by 2
Efficacy of Habb-e-Asab in diabetic peripheral neuropathy: a randomized placebo control study
Nizamdeen, F. N., Quamri, M. A., & Alam, M. A. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0330 · Cited by 2
Gandhi, T., Patel, A., & Purohit, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90583-1.00034-9 · Cited by 4
Perbaikan Klinis Kaki Diabetik Menggunakan Terapi Akupunktur
Indra, T., Gayatri, D., Dahlia, D., & Arista, L. (2022) · Jurnal Keperawatan Silampari · doi:10.31539/jks.v5i2.3481 · Cited by 2
“Menurut Ang et al., (2018) Penatalaksanaan neuropati diabetik yaitu preventif diantaranya kontrol glukosa, modifikasi gaya hidup.”
Diagnosis and Treatment of Neuropathic Ankle Fractures
Czerwonka, N., Yi, A., & Miller, C. P. (2022) · JBJS Reviews · doi:10.2106/jbjs.rvw.22.00122 · Cited by 1
Diabetic Peripheral Neuropathy: Is it Underdiagnosed?
Pinzon, R. T., Kes, M., & Rosa De Lima, R. (2020) · Asian Journal of Biological Sciences · doi:10.3923/ajbs.2020.168.172 · Cited by 1
Underlying Mechanisms and Advances in Management of Chronic Pain in Diabetes Mellitus
Kilcoyne, J., & Starkweather, A. R. (2020) · Topics in Pain Management · doi:10.1097/01.tpm.0000717700.03590.b6 · Cited by 1
Wirastuti, K., Sari, A. N., Dewi, D. A., Setyaningrum, W. A., & Hussaana, A. (2023) · Jurnal Sains Farmasi & Klinis · doi:10.25077/jsfk.10.2.205-210.2023
EFFECT OF SCIATIC NERVE MOBILIZATION ON LOWER LIMB FUNCTION AMONG SUBJECTS WITH DIABETIC NEUROPATHY
Meghana, T. S. S. P. (2023) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem25698
Ravindran, V., & Binitha, A. (2024) · Journal of Ayurveda Case Reports · doi:10.4103/jacr.jacr_23_23
Neuropatía autonómica cardíaca en diabéticos; estudio transversal analítico
Robayo-Bohórquez, G. A., Monroy-Díaz, Á. L., Hernández-Forero, M., & Cetina, N. F. G. (2024) · Revista Colombiana de Cardiología · doi:10.24875/rccar.23000005
Cardiac autonomic neuropathy in diabetic patients; an analytical cross-sectional study
Robayo-Bohórquez, G. A., Monroy-Díaz, Á. L., Hernández-Forero, M., & Cetina, N. F. G. (2024) · Revista Colombiana de Cardiología (English Edition) · doi:10.24875/rccare.m24000085
Rȧjeswari, S., Ponnusamy, V., Zdravković, N., Kisić, E., Padmajothi, V., Vijayalakshmi, S., Anuradha, C., Malathi, D., Ramasamy, N., Janardhan, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-78144-5 · Cited by 2
Frequency of neuropathy symptoms in diabetic patients
Gnanamoorthy, T., Paul, J., Alagesan, J., & Harikrishnan, N. (2024) · Scripta Medica · doi:10.5937/scriptamed55-52812
“НЕЙРОТРОПНІ” ВІТАМІНИ В1, В6, В12 І ДІАБЕТИЧНІ НЕЙРОПАТІЇ (огляд лiтератури)
Serhiyenko, V. A., & Сергієнко, О. (2025) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2025.1.08 · Cited by 1
Somisetty, K. G., Shetty, G. B., Sujatha, K. J., & Shetty, P. (2025) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2025.101147 · Cited by 1
“American Diabetes Association (ADA) recommends optimizing glucose control and lifestyle modifications like exercise and dietary modification to prevent or slow the progression of distal symmetric polyneuropathy in individuals with T2DM moderately, with a relative risk reduction of 5 – 9% [8].”
Complementary Therapies of Diabetic Peripheral Neuropathy and Intermittent Claudication
Ng, S. Y. (2025) · Healthcare · doi:10.3390/healthcare13212676
Mocanu, C. A., Salmen, T., Stoian, A. P., & Serafinceanu, C. (2025) · Biomedicines · doi:10.3390/biomedicines14010018
“…Diabetes Control and Complications Trial, prove that tight glycemic control can effectively prevent or modestly slow the progression of DPN and cardiovascular (CV) autonomic neuropathy, but without reversing neuronal loss, a fact that cannot be achieved even with disease-modifying treatment [9].”
Zerefos, I., Joshi, A., Namous, F., & Espiridion, E. D. (2026) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_361_25
“[1,2] Of the available pharmacotherapies, duloxetine and gabapentin, with distinct mechanisms and clinical implications, are frequently prescribed.”
Metadata
- Authors
- Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R.
- Affiliations
- University of Michigan (US)
- Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
- ORCID
- Ang, Lynn
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2018-08-01
- Volume
- 31
- Issue
- 3
- Pages
- 224-233
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC6092893
- OpenAlex
- W2886645622
- Cited by
- 55
- References
- 61
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic neuropathy, distal symmetric polyneuropathy, diabetic autonomic neuropathy, cardiac autonomic neuropathy, gastroparesis, neuropathic pain, opioid use, amputation risk, cardiovascular mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.